UA
45
-2
ZION
64
-3
NTAP
31
-5
VMC
62
-4
WFC
69
-5
AZO
55
-4
SEE
36
-4
CMG
47
-3
URI
42
-3
SIG
54
-3
UNP
29
-3
WU
42
-6
MET
63
-7
BLK
61
-5
PSX
37
-5
TMO
40
-3
DFS
47
-3
YUM
53
-3
HST
30
-2
GM
49
-3
UA
45
-2
ZION
64
-3
NTAP
31
-5
VMC
62
-4
WFC
69
-5
AZO
55
-4
SEE
36
-4
CMG
47
-3
URI
42
-3
SIG
54
-3
UNP
29
-3
WU
42
-6
MET
63
-7
BLK
61
-5
PSX
37
-5
TMO
40
-3
DFS
47
-3
YUM
53
-3
HST
30
-2
GM
49
-3
Financhill
Back

Amicus Therapeutics 10K Form

Sell
18

FOLD
Amicus Therapeutics

Last Price:
$8.16
Seasonality Move:
3.6%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-09 10Q FOLD/Amicus Therapeutics Quarterly
2023-11-08 10Q FOLD/Amicus Therapeutics Quarterly
2023-08-08 10Q FOLD/Amicus Therapeutics Quarterly
2023-05-10 10Q FOLD/Amicus Therapeutics Quarterly
2022-11-07 10Q FOLD/Amicus Therapeutics Quarterly
2022-08-04 10Q FOLD/Amicus Therapeutics Quarterly

Receive FOLD News And Ratings

See the #1 stock for the next 7 days that we like better than FOLD

FOLD Financial Statistics

Sales & Book Value

Annual Sales: $528.3M
Cash Flow: $-4.2M
Price / Cash Flow: 0
Annual Sales: $0.65
Price / Book: 13.35

Profitability

EPS (TTM): -0.18000
Net Income (TTM): $-56.1M
Gross Margin: $475.4M
Return on Equity: -35.23%
Return on Assets: -7.34%

Amicus Therapeutics Earnings Forecast

Key Amicus Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 22 years for FOLD is 89.98%.
  • The Selling, General & Administrative Expenses for FOLD have been equal to 61.21% of Gross Profit Margin.
  • The Research & Development expenses have been 20.70% of Revenue.
  • The Net Earning history of FOLD is -10.62% of Total Revenues.
  • Per Share Earnings over the last 22 years have been positive in 12 years.

Amicus Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: FOLD
CUSIP: 03152W
Website: amicusrx.com

Debt

Debt-to-Equity Ratio: 2.01
Current Ratio: 3.39
Quick Ratio: 2.36

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 10.05

FOLD Technical Analysis vs Fundamental Analysis

Sell
18
Amicus Therapeutics (FOLD) is a Sell

Is Amicus Therapeutics a Buy or a Sell?